Kopran soars with arm purchasing API facility at Gujarat

15 May 2018 Evaluate

Kopran is currently trading at Rs. 66.45, up by 1.35 points or 2.07% from its previous closing of Rs. 65.10 on the BSE.

The scrip opened at Rs. 65.35 and has touched a high and low of Rs. 66.50 and Rs. 65.35 respectively. So far 3619 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 96.40 on 16-May-2017 and a 52 week low of Rs. 54.30 on 26-Mar-2018.

Last one week high and low of the scrip stood at Rs. 68.70 and Rs. 64.00 respectively. The current market cap of the company is Rs. 284.17 crore.

The promoters holding in the company stood at 43.78%, while Institutions and Non-Institutions held 2.59% and 53.63% respectively.

Kopran’s wholly owned subsidiary - Kopran Research Laboratories has purchased Maxheal Pharmaceuticals (India), an API facility at Panoli in the state of Gujarat on Slump Sale basis.

The acquired unit will be suitably upgraded and expanded. The expansion of the unit is expected to be completed by December, 2018 to launch new line of products.

Kopran is engaged in pharmaceutical business. The company’s business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.

Kopran Share Price

135.60 -4.10 (-2.93%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×